|
"liu a"的相关文件
显示项目 6-15 / 41 (共5页)
1 2 3 4 5 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2022-03-14T12:48:30Z |
Substituted benzo[i]phenanthridines as mammalian topoisomerase-targeting agents
|
Makhey D.; Li D.; Zhao B.; Sim S.-P.; TSAI-KUN LI; Liu A.; Liu L.F.; LaVoie E.J. |
| 臺大學術典藏 |
2022-03-14T12:48:29Z |
Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)2,3-methylenedioxy-5H-dibenzo[c,h][1,6] naphthyridin-6-ones: Effect on topoisomerase-I targeting activity and cytotoxicity
|
Singh S.K.; Ruchelman A.L.; TSAI-KUN LI; Liu A.; Liu L.F.; LaVoie E.J. |
| 臺大學術典藏 |
2022-03-14T12:48:29Z |
5H-Dibenzo[c,h]1,6-naphthyridin-6-ones: Novel topoisomerase I-targeting anticancer agents with potent cytotoxic activity
|
Ruchelman A.L.; Singh S.K.; Ray A.; Wu X.H.; Yang J.-M.; TSAI-KUN LI; Liu A.; Liu L.F.; LaVoie E.J. |
| 臺大學術典藏 |
2022-03-14T12:48:28Z |
Aza-analogs of dibenzo[c,h]cinnoline: Triazachrysenes as potent topoisomerase I-targeting anticancer agents
|
Singh S.K.; Ruchelman A.L.; Zhou N.; TSAI-KUN LI; Liu A.; Liu L.F.; LaVoie E.J. |
| 臺大學術典藏 |
2022-03-14T12:48:28Z |
8,9-Methylenedioxybenzo[i]phenanthridines: Topoisomerase I-targeting activity and cytotoxicity
|
Li D.; Zhao B.; Sim S.-P.; TSAI-KUN LI; Liu A.; Liu L.F.; LaVoie E.J. |
| 臺大學術典藏 |
2022-03-14T12:48:27Z |
Nitro and amino substitution within the A-ring of 5H-8,9-dimethoxy-5-(2-N, N-dimethylaminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: Influence on topoisomerase I-targeting activity and cytotoxicity
|
Ruchelman A.L.; Kerrigan J.E.; TSAI-KUN LI; Zhou N.; Liu A.; Liu L.F.; LaVoie E.J. |
| 臺大學術典藏 |
2021-06-24T07:16:38Z |
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: A phase III randomized controlled trial in children
|
Langley J.M.; Carmona Martinez A.; Chatterjee A.; Halperin S.A.; McNeil S.; Reisinger K.S.; Aggarwal N.; LI-MIN HUANG; Peng C.-T.; Garcia-Sicilia J.; Salamanca De La Cueva I.; Caba?as F.; Trevi?o-Garza C.; Rodr?guez-Weber M.A.; De La O M.; Chandrasekaran V.; Dew? W.; Liu A.; Innis B.L.; Jain V.K. |
| 中山醫學大學 |
2021 |
Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study
|
Sheikh, S; Wei, CC; Tegzova, D; Stohl, W; de Toledo, RA; Mucenic, T; Banfi, MA; Maksimowicz-McKinnon, K; Abud-Mendoza, C; Navarra, S; Garcia, M; Garcia-De La Torre, I; Kurrasch, R; Fernandes, S; Harris, J; Muzaffar, S; Fox, NL; Liu, A; Quasny, H; Roth, D |
| 中山醫學大學 |
2021 |
SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: YEAR 2 FOLLOW-UP OF A LARGE PHASE 4, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
|
Sheikh, S; Scheinberg, M; Wei, JCC; Tegzova, D; Stohl, W; Mucenic, T; Punwaney, R; Kurrasch, R; Harris, J; Muzaffar, S; Fernandes, S; Fox, NL; Liu, A; Quasny, H; Roth, D |
| 臺大學術典藏 |
2020-12-16T08:52:11Z |
Combining procalcitonin with the qSOFA and sepsis mortality prediction
|
Yu H.;Nie L.;Liu A.;Wu K.;Hsein Y.-C.;Yen D.W.;Lee M.-T.G.;Chien-Chang Lee;Bakir M.; Yu H.; Nie L.; Liu A.; Wu K.; Hsein Y.-C.; Yen D.W.; Lee M.-T.G.; CHIEN-CHANG LEE; Bakir M. |
显示项目 6-15 / 41 (共5页)
1 2 3 4 5 > >>
每页显示[10|25|50]项目
|
